UK markets open in 6 hours 21 minutes
  • NIKKEI 225

    28,735.41
    +212.15 (+0.74%)
     
  • HANG SENG

    29,951.78
    -10.69 (-0.04%)
     
  • CRUDE OIL

    53.28
    +0.04 (+0.08%)
     
  • GOLD FUTURES

    1,868.40
    +1.90 (+0.10%)
     
  • DOW

    31,188.38
    +257.86 (+0.83%)
     
  • BTC-GBP

    25,513.21
    -93.55 (-0.37%)
     
  • CMC Crypto 200

    693.61
    -7.01 (-1.00%)
     
  • ^IXIC

    13,457.25
    +260.07 (+1.97%)
     
  • ^FTAS

    3,816.31
    +22.40 (+0.59%)
     

Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia

NICOX
·4-min read

Press Release

Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia



December 22, 2020 – release at 7:30 am CET
Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as VYZULTA® In the United States) in Colombia, where it will be marketed under the brand name CLIROPTA®.

VYZULTA is currently commercialized in the United States, Canada and Argentina and approved in 5 other territories – Colombia, Hong Kong, Mexico, Taiwan and Ukraine - for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.



Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered
royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones
payments.



Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX:
BHC).



About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage



Bryan, Garnier & Co Victor Floc’h Paris, France
Cantor Fitzgerald Louise Chen New York, U.S.
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Damien Choplain Paris, France
Oppenheimer & Co Hartaj Singh New York, U.S.

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com

Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website..

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachment